BVGH - Breaking Barriers to Development  
 
 
 
       
BVGH Mission
   
 

To save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics that address the unmet medical needs of the developing world.

Read More...

     
BVGH Reports
   
 

Data Center

BVGH Global Health Primer
August 2009

Global Health Innovators: A Collection of Case Studies
August 2009

BVGH Innovation Gap Report November 2007

BVGH Global Health Primer
October 2007

Tuberculosis Vaccines: The Case for Investment
October 2006

BVGH Report on Advance Market Commitments
February 2006

     
BVGH News
   
 

BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
January 20, 2010

BVGH Announces New CEO
December 30, 2009

BVGH Announces New Board Chair
September 15, 2009

BVGH Announces Management Changes
June 25, 2009

Symposium Fosters Creative Business Solutions to Global Health Issues

Review session highlights from the Partnering for Global Health Forum March 2008.

FDA Issues Draft Guidance on Priority Review Vouchers

BVGH  Receives $7M Grant from Gates Foundation

                                      » Archives

 

 

 

 

 

BVGH Blog: Sharing the Wealth
Blue line

February 2, 2010

Intellectual property (IP) is prized in research and development. It is the only way to legally protect your ideas and investments, and it serves as an incentive that inspires innovation and promotes scientific progress—you come up with a novel, valuable idea and you earn the rights to it. The IP system was devised for products that have commercial value, which means that sometimes it doesn’t work as well for products with high social value but little or no commercial value. This has been the subject of much ideological debate but little pragmatic action.

To read more, please click here.

BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool  
Blue line

Washington, D.C. – January 20, 2010 – BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.  The IP Pool was formed in February 2009 to aid in the discovery and development of new medicines for the treatment of 16 neglected tropical diseases, as defined by the U.S. Food and Drug Administration, in the world’s least developed countries.  By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases.

“New medicines for diseases that primarily affect the poor in developing countries have been slow in coming because although the market is large in numbers, most of the people affected and their governments cannot afford to pay even moderate prices. This means that much of the development of new medicines is taking place in innovative non-profits and academic research centers,” says Melinda Moree, Chief Executive Officer of BIO Ventures for Global Health, an independent, non-profit organization.  “For many of these academic and global health non-profit groups, however, intellectual property can be perceived as preventing rather than enabling their work. I am excited to use this new role to help those working on developing products for neglected diseases speed up their efforts by accessing the patents, technologies, and product development expertise available in the IP Pool.”

The full press release can be read here.

 
Highlight

Global Health News

The Huffington Post
February 4,
2010
Questions as Mileposts of Progress: Measuring the Progress of PDPs

Center for Global Development, February 2, 2010
A Global Tour of Drug Resistance

Nature, January 28, 2010
Editorial: Learning to Share

 

Industry News

PharmaBiz.com, February 3, 2010
TapImmune Signs R&D Collaboration with Aeras Global TB Vaccine Foundation

TropIKA.net, February 2, 2010
Towards a Dengue Vaccine: Another Candidate Enters Trials

Science News

UPI.com, February 4, 2010
New Malaria Vaccine Tests Safe, Effective

 

» Archives